Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - alteplase - powder and solvent for solution for injection/infusion - 20 milligram(s) - enzymes; alteplase

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - alteplase - powder and solvent for solution for injection/infusion - 50 milligram(s) - enzymes; alteplase

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - alteplase - powder and solvent for solution for injection/infusion - 10 milligram(s) - enzymes; alteplase

Ireland - English - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - simvastatin - oral suspension - 20 mg/5ml - hmg coa reductase inhibitors; simvastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - simvastatin - oral suspension - 40 mg/5ml - hmg coa reductase inhibitors; simvastatin

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - piperacillin, tazobactam, sodium - powder for solution for infusion - piperacillin 2 g tazobactam 0.25 g sodium 130 mg - antibacterials for systemic use

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - piperacillin, tazobactam, sodium - powder for solution for infusion - piperacillin 4 g tazobactam 0.5 g sodium 261 mg - antibacterials for systemic use

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zagro australia pty ltd - levamisole hydrochloride - oral solution/suspension - levamisole hydrochloride anthelmintic active 80.0 g/l - parasiticides

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - trastuzumab emtansine, quantity: 171 mg - injection, powder for - excipient ingredients: sodium hydroxide; sucrose; polysorbate 20; succinic acid - early breast cancer,kadcyla, as a single agent, is indicated for the adjuvant treatment of patients with her2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.,metastatic breast cancer,kadcyla, as a single agent, is indicated for the treatment of patients with her2-positive metastatic (stage iv) breast cancer who previously received trastuzumab and a taxane, separately or in combination. patients should have either:,? received prior therapy for metastatic disease, or,? developed disease recurrence during or within six months of completing adjuvant therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - trastuzumab emtansine, quantity: 106 mg - injection, powder for - excipient ingredients: sucrose; polysorbate 20; succinic acid; sodium hydroxide - early breast cancer,kadcyla, as a single agent, is indicated for the adjuvant treatment of patients with her2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.,metastatic breast cancer,kadcyla, as a single agent, is indicated for the treatment of patients with her2-positive metastatic (stage iv) breast cancer who previously received trastuzumab and a taxane, separately or in combination. patients should have either:,? received prior therapy for metastatic disease, or,? developed disease recurrence during or within six months of completing adjuvant therapy.